Stablepharma and AFT Pharmaceuticals partner on anti-infective and oncology therapeutics

Stablepharma and AFT Pharmaceuticals announced a partnership to address the multi-billion dollar anti-infective and oncology therapeutics market, and AFT's founder highlighted the companies' shared commitment to innovation and R&D.

Stablepharma and AFT Pharmaceuticals have entered a partnership aimed at the multi-billion dollar anti-infective and oncology therapeutics market. The article situates the agreement as a response to global healthcare needs and as a vehicle for advancing new treatments. The article notes AFT Pharmaceuticals is a multinational listed in Australia and New Zealand and that its leadership emphasized investment in research and development. Hartley Atkinson, AFT's founder and managing director, described the partnership as aligned with the companies' shared vision to improve healthcare. Key details: - The partnership focuses on anti-infective and oncology therapeutics targeting a multi-billion dollar market. - The article reports AFT Pharmaceuticals and Stablepharma are aligned in their vision to improve healthcare globally. - AFT's founder Hartley Atkinson is quoted as saying the collaboration is a good fit and that AFT is committed to investing in innovation and R&D. - The article notes AFT Pharmaceuticals is listed in Australia and New Zealand. Summary: The partnership is presented as a collaboration to combine efforts on anti-infective and oncology projects and to leverage R&D investment. Undetermined at this time.